ProfileGDS5678 / 1426681_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 65% 61% 62% 60% 59% 59% 60% 61% 70% 65% 62% 61% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6353760
GSM967853U87-EV human glioblastoma xenograft - Control 23.8971565
GSM967854U87-EV human glioblastoma xenograft - Control 33.6303561
GSM967855U87-EV human glioblastoma xenograft - Control 43.6970762
GSM967856U87-EV human glioblastoma xenograft - Control 53.5650160
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6428159
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6320859
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6160460
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6260961
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3966470
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9133765
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7020962
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6350361
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5180959